<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28422137</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2017</Year><Month>Apr</Month><Day>19</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Effective in vivo therapeutic IgG antibody against VP3 of enterovirus 71 with receptor-competing activity.</ArticleTitle><Pagination><StartPage>46402</StartPage><MedlinePgn>46402</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">46402</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep46402</ELocationID><Abstract><AbstractText>Passive immunization is an effective option for treatment against hand, foot and mouth disease caused by EV71, especially with cross-neutralizing IgG monoclonal antibodies. In this study, an EV71-specific IgG2a antibody designated 5H7 was identified and characterized. 5H7 efficiently neutralizes the major EV71 genogroups (A, B4, C2, C4). The conformational epitope of 5H7 was mapped to the highly conserved amino acid position 74 on VP3 capsid protein using escape mutants. Neutralization with 5H7 is mediated by the inhibition of viral attachment, as revealed by virus-binding and post-attachment assays. In a competitive pull-down assay with SCARB2, 5H7 blocks the receptor-binding site on EV71 for virus neutralization. Passive immunization of chimeric 5H7 protected 100% of two-week-old AG129 mice from lethal challenge with an EV71 B4 strain for both prophylactic and therapeutic treatments. In contrast, 10D3, a previously reported neutralizing antibody that takes effect after virus attachment, could only confer prophylactic protection. These results indicate that efficient interruption of viral attachment is critical for effective therapeutic activity with 5H7. This report documents a novel universal neutralizing IgG antibody for EV71 therapeutics and reveals the underlying mechanism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Animal Health Biotechnology, Temasek Life Sciences Laboratory, Republic of Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Qingyong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Animal Health Biotechnology, Temasek Life Sciences Laboratory, Republic of Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chin</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Singapore Immunology Network; Agency for Science; Technology and Research (A*STAR), Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Animal Health Biotechnology, Temasek Life Sciences Laboratory, Republic of Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Vincent Tak Kwong</ForeName><Initials>VTK</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Republic of Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Cheng-I</ForeName><Initials>CI</Initials><AffiliationInfo><Affiliation>Singapore Immunology Network; Agency for Science; Technology and Research (A*STAR), Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwang</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Animal Health Biotechnology, Temasek Life Sciences Laboratory, Republic of Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Republic of Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Animal Health Biotechnology, Temasek Life Sciences Laboratory, Republic of Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Preventive Veterinary Medicine, and Zhejiang Provincial Key Laboratory of Preventive Veterinary Medicine, College of Animal Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011991">Receptors, Virus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011991" MajorTopicYN="N">Receptors, Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053585" MajorTopicYN="N">Virus Attachment</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28422137</ArticleId><ArticleId IdType="pmc">PMC5395816</ArticleId><ArticleId IdType="doi">10.1038/srep46402</ArticleId><ArticleId IdType="pii">srep46402</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee K. Y. Enterovirus 71 infection and neurological complications. Korean J Pediatr 59, 395&#x2013;401 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099286</ArticleId><ArticleId IdType="pubmed">27826325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K. P. et al.. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 9, 78&#x2013;85 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L. Y. et al.. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 18, 1092&#x2013;6 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10608631</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum L. C., Wong K. T., Lam S. K., Chua K. B. &amp; Goh A. Y. Neurogenic pulmonary oedema and enterovirus 71 encephalomyelitis. Lancet 352, 1391 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9802304</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C. C. et al.. Neurologic complications in children with enterovirus 71 infection. N Engl J Med 341, 936&#x2013;42 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10498488</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F. et al.. Enterovirus 71 outbreak in the People&#x2019;s Republic of China in 2008. J Clin Microbiol 47, 2351&#x2013;2 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M. Y. et al.. Characterization of enterovirus 71 infection and associated outbreak of Hand, Foot, and Mouth Disease in Shawo of China in 2012. Sci Rep 6, 38451 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5150535</ArticleId><ArticleId IdType="pubmed">27941929</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q. Y., Wang Y., Bian L., Xu M. &amp; Liang Z. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines 15, 599&#x2013;606 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P. C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26, 91&#x2013;107 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng Q., He F. &amp; Kwang J. Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines. Viruses 7, 6441&#x2013;57 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690872</ArticleId><ArticleId IdType="pubmed">26670245</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X. et al.. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol 19, 424&#x2013;9 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P., Perera R., Cardosa J., Kuhn R. J. &amp; Rossmann M. G. Crystal structure of human enterovirus 71. Science 336, 1274 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener T. K. et al.. Characterization of a monoclonal antibody against the 3D polymerase of enterovirus 71 and its use for the detection of human enterovirus A infection. J Virol Methods 180, 75&#x2013;83 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22226793</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee K. K. et al.. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol 84, 3339&#x2013;50 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838098</ArticleId><ArticleId IdType="pubmed">20089660</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H. L. et al.. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 26, 2882&#x2013;9 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18450335</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener T. K., Premanand B. &amp; Kwang J. Immune responses to baculovirus-displayed enterovirus 71 VP1 antigen. Expert Rev Vaccines 12, 357&#x2013;64 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23560917</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L. et al.. Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop. Theranostics 4, 498&#x2013;513 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964443</ArticleId><ArticleId IdType="pubmed">24669278</ArticleId></ArticleIdList></Reference><Reference><Citation>He F. et al.. Development of a sensitive and specific epitope-blocking ELISA for universal detection of antibodies to human enterovirus 71 strains. PLoS One 8, e55517 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3561296</ArticleId><ArticleId IdType="pubmed">23383215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener T. K., Jia Q., Meng T., Chow V. T. &amp; Kwang J. A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved &#x201c;knob&#x201d; region of VP3 protein. PLoS Negl Trop Dis 8, e2895 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038473</ArticleId><ArticleId IdType="pubmed">24875055</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z. et al.. In vivo time-related evaluation of a therapeutic neutralization monoclonal antibody against lethal enterovirus 71 infection in a mouse model. PLoS One 9, e109391 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4184856</ArticleId><ArticleId IdType="pubmed">25279734</ArticleId></ArticleIdList></Reference><Reference><Citation>Elgundi Z., Reslan M., Cruz E., Sifniotis V. &amp; Kayser V. The state-of-play and future of antibody therapeutics. Adv Drug Deliv Rev (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27916504</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong W. X. et al.. A non-mouse-adapted enterovirus 71 (EV71) strain exhibits neurotropism, causing neurological manifestations in a novel mouse model of EV71 infection. J Virol 86, 2121&#x2013;31 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3302383</ArticleId><ArticleId IdType="pubmed">22130542</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahnemann H. G. Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Arch Virol 47, 47&#x2013;56 (1975).</Citation><ArticleIdList><ArticleId IdType="pubmed">167679</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T., Kiener T. K. &amp; Kwang J. RNA polymerase I-driven reverse genetics system for enterovirus 71 and its implications for vaccine production. Virol J 9, 238 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3493273</ArticleId><ArticleId IdType="pubmed">23072515</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S. et al.. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 15, 798&#x2013;801 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A., Dadachova E. &amp; Pirofski L. A. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2, 695&#x2013;703 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15372080</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T. C. et al.. Diseases caused by enterovirus 71 infection. Pediatr Infect Dis J 28, 904&#x2013;10 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">20118685</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L. et al.. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice. Vaccine 33, 6596&#x2013;603 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26529072</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X. et al.. Structural Basis for Recognition of Human Enterovirus 71 by a Bivalent Broadly Neutralizing Monoclonal Antibody. PLoS Pathog 12, e1005454 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4777393</ArticleId><ArticleId IdType="pubmed">26938634</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S., Singh S., Poh C. L. &amp; Chow V. T. The hand, foot and mouth disease virus capsid: sequence analysis and prediction of antigenic sites from homology modelling. Appl Bioinformatics 1, 43&#x2013;52 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">15130856</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y. et al.. Characterization of the antibody response against EV71 capsid proteins in Chinese individuals by NEIBM-ELISA. Sci Rep 5, 10636 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4448526</ArticleId><ArticleId IdType="pubmed">26023863</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y. I. et al.. Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection. Vaccine 33, 6604&#x2013;10 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26529069</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y., Ng Q., Jia Q., Kwang J. &amp; He F. A novel humanized antibody neutralizes H5N1 influenza virus via two different mechanisms. J Virol 89, 3712&#x2013;22 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4403434</ArticleId><ArticleId IdType="pubmed">25609802</ArticleId></ArticleIdList></Reference><Reference><Citation>He F., Prabakaran M., Rajesh Kumar S., Tan Y. &amp; Kwang J. Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice. Antiviral Res 105, 143&#x2013;51 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24637255</ArticleId></ArticleIdList></Reference><Reference><Citation>He F. et al.. Effective intranasal therapeutics and prophylactics with monoclonal antibody against lethal infection of H7N7 influenza virus. Antiviral Res 100, 207&#x2013;14 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23954322</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei P. et al.. Pains and Gains from China&#x2019;s Experiences with Emerging Epidemics: From SARS to H7N9. Biomed Res Int 2016, 5717108 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4971293</ArticleId><ArticleId IdType="pubmed">27525272</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y. et al.. Interaction of the poliovirus receptor with poliovirus. Proc Natl Acad Sci USA 97, 79&#x2013;84 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC26619</ArticleId><ArticleId IdType="pubmed">10618374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X. et al.. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J Virol 88, 72&#x2013;81 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3911748</ArticleId><ArticleId IdType="pubmed">24131712</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim X. F. et al.. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS One 7, e29751 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261156</ArticleId><ArticleId IdType="pubmed">22279543</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson A. L., Dhimolea E. &amp; Reichert J. M. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9, 767&#x2013;74 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20811384</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadzadeh V., Farajnia S., Feizi M. A. &amp; Nejad R. A. Antibody humanization methods for development of therapeutic applications. Monoclon Antib Immunodiagn Immunother 33, 67&#x2013;73 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24746146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigounas G., Harindranath N., Donadel G. &amp; Notkins A. L. Half-life of polyreactive antibodies. J Clin Immunol 14, 134&#x2013;40 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">8195315</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P. et al.. Neutralizing antibodies can initiate genome release from human enterovirus 71. Proc Natl Acad Sci USA 111, 2134&#x2013;9 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3926013</ArticleId><ArticleId IdType="pubmed">24469789</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>